ClinicalTrials.gg
CompletedNCT00574288Updated Apr 27, 2018Results posted

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

A Phase 2 interventional study of Part 1: Daratumumab and Part 2: Daratumumab in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
37th of 132
104 · median 50
Started
2008
the only one that year
Phase 2
73 of 132
7 open now
Registered
1st of 132
by date
Lead sponsor
17 of 132
Janssen Research & Development, LLC

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 37th largest by enrollment, is the only one that started in 2008, is one of 73 in phase 2, and was the 1st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.

Read the detailed description

This study is conducted in two parts. In part I, participants are enrolled into cohorts at increasing dose levels. Participant safety and efficacy during part I will determine the doses used for Part II. In part II participants will be enrolled into one of two sequential treatment arms using two of the doses defined in part 1 of the study. Part II was 5 cohorts, 3 with 8 milligram per kilogram (mg/kg) and 2 with 16 mg/kg. Part I and all but the last cohort in Part II were dosed with Phase 1/ 2 drug product. The last cohort in Part II was dosed with Phase 3 drug product. Both Part I and Part II are open-label/unmasked.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Daratumumab
  • Safety
  • HuMax-CD38
  • Dose-escalation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple myeloma (MM) requiring systemic therapy
  • Age greater than or equal to (>=) 18 years
  • (ECOG) performance status of 0-2
  • greater than (>) 3 months
  • from or refractory to two or more different prior therapies
  • Signed

Exclusion criteria

Exclusion criteria

  • Plasma cell leukemia defined as a plasma cell count > 2000/millimeter\^3 (mm\^3)
  • Known amyloidosis
  • Participants who previously have received an stem cell transplant
  • Sensory or motor neuropathy of >= grade 3
  • Past or current
  • Chronic or ongoing active infectious disease
  • cardiac disease
  • Significant concurrent, uncontrolled medical condition including, but not limited to, renal (except related to MM), hepatic, hematological except MM, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
  • A baseline as corrected by Fridericia's formula > 470 millisecond (msec) for female participants or > 450 msec for male participants or a complete left bundle branch block (defined as a QRS interval >= 120 msec in left bundle branch block form)
  • Hypokalemia
  • Clinical signs of meningeal involvement of MM
  • Known severe or asthma defined as (FEV1) less than (\<) 60 percentage (%) of expected
  • History of significant cerebrovascular disease
  • Known seropositivity
  • Positive serology for
  • Screening laboratory values
  • Concomitant
  • Other chemotherapy that is or may be active against myeloma within 3 weeks prior to Visit 2 (Part 1) or the first dose of daratumumab (Part 2). However, corticosteroid for myeloma (less than a 4-day course) could be administered within 1 week before Visit 2 (Part 1) or the first dose of daratumumab (Part 2)
  • Known to components of the product or severe allergic or anaphylactic reactions to humanized products
  • Participants who have received treatment with any nonmarket drug substance within 4 weeks before the first dose of daratumumab
  • Current participation in any other interventional clinical trial
  • Participants known or suspected of not being able to comply with a trial protocol (example, due to alcoholism, drug dependency, or psychological disorder)
  • Breastfeeding women or women with a positive pregnancy test at Screening
  • Women of not willing to use adequate , defined as hormonal birth control or intrauterine device, during the trial and for 1 year after the last dose of daratumumab. For participants in the United States, the use of a double-barrier method is also considered adequate
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Dose Escalation: Daratumumab

    Drug: Part 1: Daratumumab · Other: Methylprednisolone

  • Experimental
    Dose Expansion: Daratumumab

    Drug: Part 2: Daratumumab · Other: Methylprednisolone · Other: Dexamethasone

Interventions

  • First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.

    Also known as: HuMax-CD38

  • In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.

    Also known as: HuMax-CD38

  • OtherMethylprednisolone

    Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4. Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions.

  • OtherDexamethasone

    Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2)

Secondary outcomes

  1. Overall Response Rate

    Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.

    Time frame: Up to Week 28 (for Part 1) and Week 27 (for Part 2)

  2. Part 1: Time to Response

    Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Kaplan-Meier method was used to estimate the distribution of time to response and time to best response.

    Time frame: Up to Week 28

  3. Part 2: Time to Progression (TTP)

    TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 g/dL); urine M-component and/or (the absolute increase must be \>=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method.

    Time frame: Up to Week 27

  4. Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier

    Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria.

    Time frame: Up to Week 27

  5. Part 2: Progression-Free Survival

    Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.

    Time frame: Up to Week 27

  6. Part 2: Time to Response

    Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response.

    Time frame: Up to Week 27

  7. Part 2: Overall Survival

    Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.

    Time frame: Approximately 3 years

07

Results

Posted Mar 9, 2017

Participant flow

Participant flow — Overall Study
MilestonePart 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kg
Started2033333042
Completed00011414
Not completed2033222628
Withdrew: Adverse event2000100
Withdrew: Death000002521
Withdrew: Lost to follow-up0000012
Withdrew: Study terminated by sponsor0000005
Withdrew: Progressive disease17232100
Withdrew: Other1100000

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2)
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPart 1: Daratumumab Less Than (<) 4 mg/kgPart 1: Daratumumab 4 mg/kgPart 1:Daratumumab 8 mg/kgPart 1: Daratumumab 16 mg/kgPart 1:Daratumumab 24 mg/kgPart 2: Daratumumab 8 mg/kgPart 2: Daratumumab 16 mg/kg
Number of Participants With Adverse Events1933333041
SecondaryOverall Response Rate

Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.

Time frame:
Up to Week 28 (for Part 1) and Week 27 (for Part 2)
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsPart 1: Daratumumab 4 mg/kgPart 1:Daratumumab 8 mg/kgPart 1: Daratumumab 16 mg/kgPart 1:Daratumumab 24 mg/kgPart 2: Daratumumab 8 mg/kgPart 2: Daratumumab 16 mg/kg
Overall Response Rate33.3 (0.8 to 90.6)0 (0 to 0)33.3 (0.8 to 90.6)66.7 (9.4 to 99.2)10.0 (2.1 to 26.5)35.7 (21.6 to 52.0)
SecondaryPart 1: Time to Response

Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Kaplan-Meier method was used to estimate the distribution of time to response and time to best response.

Time frame:
Up to Week 28
Reported as:
Median · months
Part 1: Time to Response
monthsPart 1: Daratumumab 4 mg/kgDaratumumab 8 mg/kgDaratumumab 16 mg/kgPart 1:Daratumumab 24 mg/kg
Time to first responseNA (1.2 to NA)NA (NA to NA)8.4 (NA to NA)1.9 (0.5 to 1.9)
Time to best responseNA (1.2 to NA)NA (NA to NA)8.4 (NA to NA)1.9 (0.5 to 1.9)
SecondaryPart 2: Time to Progression (TTP)

TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 g/dL); urine M-component and/or (the absolute increase must be \>=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method.

Time frame:
Up to Week 27
Reported as:
Median · months
Part 2: Time to Progression (TTP)
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Part 2: Time to Progression (TTP)2.4 (1.4 to 3.5)5.6 (4.7 to NA)
SecondaryPart 2: Duration of Response as Assessed Using the Method of Kaplan-Meier

Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria.

Time frame:
Up to Week 27
Reported as:
Median · months
Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier6.9 (6.2 to 10.6)NA (5.6 to NA)
SecondaryPart 2: Progression-Free Survival

Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.

Time frame:
Up to Week 27
Reported as:
Median · months
Part 2: Progression-Free Survival
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Part 2: Progression-Free Survival2.4 (1.4 to 3.5)5.6 (4.2 to 8.1)
SecondaryPart 2: Time to Response

Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response.

Time frame:
Up to Week 27
Reported as:
Mean · months
Part 2: Time to Response
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Time to first response1.36 ± 0.7741.33 ± 0.955
Time to best response1.36 ± 0.7742.46 ± 2.800
Time to VGPR or better response—0.49 ± 0.000
SecondaryPart 2: Overall Survival

Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.

Time frame:
Approximately 3 years
Reported as:
Median · months
Part 2: Overall Survival
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Part 2: Overall Survival18.2 (7.5 to 22.6)34.3 (19.9 to NA)

Adverse events

Collected over Up to Week 28 (for Part 1) and approximately 2.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - <4 mg/kg—7/20 (35%)19/20 (95%)
Part 1 - 4 mg/kg—0/3 (0%)3/3 (100%)
Part 1 - 8 mg/kg—1/3 (33.3%)3/3 (100%)
Part 1 - 16 mg/kg—2/3 (66.7%)3/3 (100%)
Part 1 - 24 mg/kg—2/3 (66.7%)3/3 (100%)
Part 2 - 8 mg/kg—12/30 (40%)30/30 (100%)
Part 2 - 16 mg/kg—16/42 (38.1%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPart 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kg
PyrexiaGeneral disorders1/200/31/31/30/31/302/42
Metapneumovirus InfectionInfections and infestations0/200/31/30/30/30/300/42
PneumoniaInfections and infestations0/200/30/31/30/33/303/42
Urinary Tract InfectionInfections and infestations0/200/30/30/31/30/300/42
Confusional StatePsychiatric disorders0/200/30/31/30/30/300/42
BronchospasmRespiratory, thoracic and mediastinal disorders1/200/30/30/31/30/300/42
Crossmatch IncompatibleInvestigations0/200/30/30/30/30/303/42
AnaemiaBlood and lymphatic system disorders1/200/30/30/30/31/300/42
ThrombocytopeniaBlood and lymphatic system disorders1/200/30/30/30/31/300/42
Atrial FibrillationCardiac disorders1/200/30/30/30/30/300/42
Most frequent other events
Showing 10 of 97
Most frequent other events
EventPart 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kg
ProteinuriaRenal and urinary disorders9/201/33/31/31/30/300/42
HypertensionVascular disorders2/200/32/30/30/30/303/42
FatigueGeneral disorders2/200/30/30/30/313/3019/42
PyrexiaGeneral disorders7/200/30/31/30/312/309/42
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders1/200/30/30/30/312/3010/42
NasopharyngitisInfections and infestations2/200/30/30/31/37/3016/42
MonocytopeniaBlood and lymphatic system disorders2/201/30/30/30/30/300/42
PalpitationsCardiac disorders0/201/30/30/30/30/301/42
DiarrhoeaGastrointestinal disorders1/201/30/30/31/39/306/42
Lip OedemaGastrointestinal disorders0/201/30/30/30/30/300/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kgTotal
<=18 years00000000
Between 18 and 65 years112232212263
>=65 years9110192041
Age, Continuous
Age, Continuous(years)Part 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kgTotal
Mean61.8 ± 9.2464 ± 261.3 ± 6.1153 ± 1.7359 ± 9.5458.6 ± 10.0563.8 ± 8.2761.4 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kgTotal
Female7200091533
Male131333212771
Region of Enrollment
Region of Enrollment(Participants)Part 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kgTotal
Denmark1112205930
Netherlands4211214832
Sweden5000151122
United States0000061420
No. of Prior Lines of Therapy
No. of Prior Lines of Therapy(Participants)Part 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kgTotal
<= 3 Lines2200061626
> 3 Lines181333242678
Refractory to proteasome inhibitor (PI)/immunomodulatory agent (IMiD)
Refractory to proteasome inhibitor (PI)/immunomodulatory agent (IMiD)(Participants)Part 1 - <4 mg/kgPart 1 - 4 mg/kgPart 1 - 8 mg/kgPart 1 - 16 mg/kgPart 1 - 24 mg/kgPart 2 - 8 mg/kgPart 2 - 16 mg/kgTotal
Both a PI and IMiD02312192754
PI only01000236
IMiD only000116412
None2000103832
08

Study locations

7 sites
  • Boston, Massachusetts, United States
  • Copenhagen Ø, Denmark
  • Vejle, Denmark
  • Amsterdam, Netherlands
  • Utrecht, Netherlands
  • Huddinge, Sweden
  • Lund, Sweden
09

References and documents

Publications

  • Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. doi: 10.1016/S2352-3026(20)30081-8. PubMed 32470437 ↗
  • Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11. PubMed 30536810 ↗
  • Krejcik J, Frerichs KA, Nijhof IS, van Kessel B, van Velzen JF, Bloem AC, Broekmans MEC, Zweegman S, van Meerloo J, Musters RJP, Poddighe PJ, Groen RWJ, Chiu C, Plesner T, Lokhorst HM, Sasser AK, Mutis T, van de Donk NWCJ. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12. PubMed 29025767 ↗
  • Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15. PubMed 27307294 ↗
  • Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26. PubMed 26308596 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2008 to primary completion in Jan 2015, 81 months.

Results were first posted in Mar 2017, 2 years 2 months after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 81 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2007
First posted
Dec 17, 2007
StartActual
Mar 26, 2008
Primary completionActual
Jan 9, 2015
CompletionActual
Apr 3, 2017
Results first posted
Mar 9, 2017
Last update
Apr 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00574288
Responsible party
Sponsor
First posted
Dec 17, 2007
Start date
Mar 26, 2008
Primary completion
Jan 9, 2015
Completion
Apr 3, 2017
Results posted
Mar 9, 2017
Last update
Apr 27, 2018

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion